Peroxitech Awarded NIH Grant to Develop a Novel Therapeutic Approach to Expend and Improve Lung Transplant Organ Pool
Philadelphia – August 30, 2022 – Peroxitech Inc., an emerging biopharmaceutical company, has been awarded an NIH grant to further develop a novel therapeutic treatment to extend and improve the storage and viability of donor lungs for transplant.
One of the major challenges in lung transplantation is the low availability of healthy donor lungs and no means of protecting donor lungs from oxidative damage during entire transplantation process. With this grant, Peroxitech will evaluate a novel therapeutic treatment that may improve lung protection and extend lung transportation duration with the goal of improving outcomes. This grant will be led by Shampa Chatterjee, PhD. Research Associate Professor of Physiology at the University of Pennsylvania School of Medicine.
“If successful, this therapeutic approach would be a significant breakthrough in organ transplantation,” stated Thomas Han, CEO & Co-Founder of Peroxitech, “it has the potential to be applied broadly to improve donor organ viability and increase availability for all transplant patients.”
About Peroxitech
Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury. The company was launched the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures and was seeded at Xontogeny. In addition to the first clinical indication, Peroxitech is also evaluating our lead compound for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.
One of the major challenges in lung transplantation is the low availability of healthy donor lungs and no means of protecting donor lungs from oxidative damage during entire transplantation process. With this grant, Peroxitech will evaluate a novel therapeutic treatment that may improve lung protection and extend lung transportation duration with the goal of improving outcomes. This grant will be led by Shampa Chatterjee, PhD. Research Associate Professor of Physiology at the University of Pennsylvania School of Medicine.
“If successful, this therapeutic approach would be a significant breakthrough in organ transplantation,” stated Thomas Han, CEO & Co-Founder of Peroxitech, “it has the potential to be applied broadly to improve donor organ viability and increase availability for all transplant patients.”
About Peroxitech
Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury. The company was launched the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures and was seeded at Xontogeny. In addition to the first clinical indication, Peroxitech is also evaluating our lead compound for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.